Congress Wealth Management LLC DE Sells 68,660 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Congress Wealth Management LLC DE trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.0% in the fourth quarter, HoldingsChannel reports. The firm owned 229,765 shares of the biopharmaceutical company’s stock after selling 68,660 shares during the quarter. Congress Wealth Management LLC DE’s holdings in Halozyme Therapeutics were worth $10,985,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Raymond James Financial Inc. bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $21,838,000. Vanguard Group Inc. boosted its position in Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock worth $634,999,000 after purchasing an additional 386,618 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after purchasing an additional 251,711 shares during the period. Victory Capital Management Inc. increased its position in shares of Halozyme Therapeutics by 60.0% during the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock valued at $31,112,000 after purchasing an additional 243,940 shares during the last quarter. Finally, Boston Trust Walden Corp raised its stake in shares of Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after purchasing an additional 191,465 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on HALO shares. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, Benchmark reissued a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $64.02 on Tuesday. The firm has a market capitalization of $7.91 billion, a P/E ratio of 18.66, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The business has a fifty day moving average price of $58.39 and a 200-day moving average price of $54.68.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,697 shares of company stock valued at $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.